From Researchers to Researchers.
Atlas Antibodies has an extraordinary story. The company was founded in 2006 by researchers from the prestigious Human Protein Atlas project, who wanted to make the unique antibodies used in the project available to fellow researchers worldwide.
The Human Protein Atlas was initiated in 2003 by Swedish researchers, headed by Professor Mathias Uhlén, and is funded by the Knut and Alice Wallenberg Foundation. It is a unique world-leading effort to create a complete map of human protein expression and localization in normal tissues, cancers, and cell lines. The project launched the first version of the entire human tissue proteome in 2016 as the Tissue Atlas, the subcellular proteome in 2017, and continues to add additional layers of knowledge exploring the human proteome.
Critical for the project's success was the availability of highly specific antibodies for all human proteins. As it was impossible to source all of the antibodies with the required quality needed, a standardized manufacturing process with rigorous quality control was developed. The in-house development ensured that the antibodies met the high level of specificity and selectivity required for the project to succeed.
The first version of the Human Protein Atlas database was released at the Human Proteome Organizations (HUPO) meeting in 2005. It received an overwhelmingly positive response. Shortly afterward the Human Protein Atlas researchers started to be asked by fellow researchers if they could obtain the antibodies for use in their research. This led to the establishment of Atlas Antibodies in 2006 to commercialize the antibodies developed by the Human Protein Atlas project.
Atlas Antibodies and the Human Protein Atlas share a collaborative relationship aimed at advancing the understanding of the human proteome.
Atlas Antibodies specializes in producing rigorously validated antibodies, which are crucial tools for protein detection such as Triple A Polyclonals and PrecisA Monoclonals.
These antibodies are utilized within the Human Protein Atlas project to immunostain tissues and cells, enabling the comprehensive mapping of protein expression across various biological samples. Through this partnership, Atlas Antibodies and the Human Protein Atlas contribute to the ambitious goal of cataloging all human proteins, furthering research in biology and medicine.
These antibodies originating from the Human Protein Atlas project are available under the brand Atlas Antibodies Advanced Polyclonals (Triple A Polyclonals™). The Triple A Polyclonals are since then been manufactured by Atlas Antibodies in our facilities in Sweden and distributed worldwide.
PrecisA Monoclonals™, precise, accurate, and targeted monoclonal antibodies. In 2012, Atlas Antibodies started in-house development of mouse monoclonal antibodies against a selected number of targets. We have named them PrecisA Monoclonals to reflect the core values at Atlas Antibodies and our Swedish origin. We offer a growing portfolio of monoclonals for use in various applications and research areas. The Swedish word "precisa" stands for precise, accurate, and targeted. It is a perfect description of our mouse monoclonal antibodies.
In 2014, we expanded our product offering to include PrEST Antigens™, recombinant protein fragments used as immunogens for generating Triple A Polyclonals, and PrecisA Monoclonals. The PrEST Antigens are recombinant human Protein Epitope Signature Tags (PrESTs) consisting of 50-150 amino acids and are designed to have as low sequence identity as possible to other human proteins. The PrEST Antigens are provided as complements to our antibodies for control experiments.
In 2024 Atlas Antibodies released MolBoolean™ a novel in situ proximity technology for protein-protein interaction studies.. MolBoolean™ mouse/rabbit is a kit for in situ protein proximity analysis in tissue and cells. The MolBoolean™ assay utilizes a proprietary oligonucleotide setup that enables the simultaneous detection of both free and interacting (~40 nm proximity) fractions for two proteins of interest (protein A, protein B and interaction proteins AB).
For every therapeutic discovery to be enhanced by our solutions.
Through our expertise and unique heritage, we provide innovative and high-quality solutions to researchers around the world.
By doing so, we enable ground-breaking medical discovery, better diagnosis, and patient outcomes.
Our success has been acknowledged by both the Swedish scientific community, where Atlas Antibodies has been nominated as one of Sweden's most promising young technology companies for three consecutive years, and by the Swedish daily financial paper Dagens Industri as one of the fastest-growing companies in Sweden. In 2014, Atlas Antibodies was also the proud recipient of the SwedishLabTech Award for our contributions to the antibody-based exploration of the human proteome using TripleA Polyclonals. In 2018, we were delighted to be Highly Commended in CiteAb's 2018 awards for "Most exciting antibody validation initiative".
HistoCyte Laboratories offers high quality, reproducible and cost-effective analyte control material for same-slide use in histopathology. Current products include controls for PD-L1, Her2, ER, PR, EML4-ALK, ROS1, NPM-ALK, HPV and p16, with many more in development. Our latest controls for mismatch repair (MMR) consist of four different cell lines with loss of and intact expression for MLH1, PMS2, MSH2 and MSH6.
Formed in 2014, HistoCyte Laboratories has established a significant presence in important markets such as the UK and USA. The company has a strong growth trajectory that is expected to accelerate as acceptance of cell line controls increases rapidly.
Read more: Atlas Antibodies acquires HistoCyte Laboratories Ltd.
Visit HistoCyte Website
evitria is an established, global antibody expression service provider located in Zurich, Switzerland. They specialize in CHO-based transient expression of antibodies - including bispecific and fusion antibodies - and other proteins. Since its inception in 2010, evitria has been singularly focused on transient expression of recombinant antibodies in CHO cells. This long-standing and deep focus allows the company to deliver antibodies of exceptional quality with outstanding service levels with respect to turnaround time and material quantity. With a track record of more than 75,000 transfections performed and more than 12,000 antibody-based molecules purified, evitria is a trusted partner for full outsourcing of antibody production for research purposes, to manage capacity bottlenecks, or to pursue single projects.
Read more: Atlas Antibodies acquires evitria.